GURUFOCUS.COM » STOCK LIST » Basic Materials » Chemicals » Novonesis (Novozymes) B (OCSE:NSIS B) » Definitions » Piotroski F-Score

Novonesis (Novozymes) B (OCSE:NSIS B) Piotroski F-Score : 5 (As of Jul. 21, 2025)


View and export this data going back to 2000. Start your Free Trial

What is Novonesis (Novozymes) B Piotroski F-Score?

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Novonesis (Novozymes) B has an F-score of 5 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for Novonesis (Novozymes) B's Piotroski F-Score or its related term are showing as below:

OCSE:NSIS B' s Piotroski F-Score Range Over the Past 10 Years
Min: 4   Med: 6   Max: 9
Current: 5

During the past 13 years, the highest Piotroski F-Score of Novonesis (Novozymes) B was 9. The lowest was 4. And the median was 6.


Novonesis (Novozymes) B Piotroski F-Score Historical Data

The historical data trend for Novonesis (Novozymes) B's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novonesis (Novozymes) B Piotroski F-Score Chart

Novonesis (Novozymes) B Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.00 7.00 5.00 6.00 7.00

Novonesis (Novozymes) B Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Dec24 Mar25
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.00 5.00 4.00 7.00 5.00

Competitive Comparison of Novonesis (Novozymes) B's Piotroski F-Score

For the Specialty Chemicals subindustry, Novonesis (Novozymes) B's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Novonesis (Novozymes) B's Piotroski F-Score Distribution in the Chemicals Industry

For the Chemicals industry and Basic Materials sector, Novonesis (Novozymes) B's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Novonesis (Novozymes) B's Piotroski F-Score falls into.


;
;

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar25) TTM:Last Year (Dec23) TTM:
Net Income was 248.295 + 228.383 + 1804.017 + 1387.319 = kr3,668 Mil.
Cash Flow from Operations was 1316.038 + 2624.17 + 3667.695 + 793.606 = kr8,402 Mil.
Revenue was 6363.956 + 7300.805 + 14928.817 + 8037.498 = kr36,631 Mil.
Gross Profit was 2726.771 + 2995.106 + 7774.648 + 4432.707 = kr17,929 Mil.
Average Total Assets from the begining of this year (Dec23)
to the end of this year (Mar25) was
(28393.116 + 0 + 113834.934 + 113324.17 + 112308.67) / 5 = kr91965.2225 Mil.
Total Assets at the begining of this year (Dec23) was kr28,393 Mil.
Long-Term Debt & Capital Lease Obligation was kr9,466 Mil.
Total Current Assets was kr14,514 Mil.
Total Current Liabilities was kr8,728 Mil.
Net Income was 783.395 + 605.844 + 933.965 + 1634.538 = kr3,958 Mil.

Revenue was 4619.417 + 4215.929 + 4446.31 + 9056.669 = kr22,338 Mil.
Gross Profit was 2501.058 + 2335.404 + 2392.784 + 4881.255 = kr12,111 Mil.
Average Total Assets from the begining of last year (Dec22)
to the end of last year (Dec23) was
(27940.191 + 28262.085 + 28220.809 + 28475.944 + 28393.116) / 5 = kr28258.429 Mil.
Total Assets at the begining of last year (Dec22) was kr27,940 Mil.
Long-Term Debt & Capital Lease Obligation was kr0 Mil.
Total Current Assets was kr9,462 Mil.
Total Current Liabilities was kr7,250 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Novonesis (Novozymes) B's current Net Income (TTM) was 3,668. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Novonesis (Novozymes) B's current Cash Flow from Operations (TTM) was 8,402. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Dec23)
=3668.014/28393.116
=0.12918674

ROA (Last Year)=Net Income/Total Assets (Dec22)
=3957.742/27940.191
=0.1416505

Novonesis (Novozymes) B's return on assets of this year was 0.12918674. Novonesis (Novozymes) B's return on assets of last year was 0.1416505. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Novonesis (Novozymes) B's current Net Income (TTM) was 3,668. Novonesis (Novozymes) B's current Cash Flow from Operations (TTM) was 8,402. ==> 8,402 > 3,668 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Mar25)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec23 to Mar25
=9465.84/91965.2225
=0.10292847

Gearing (Last Year: Dec23)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec22 to Dec23
=0/28258.429
=0

Novonesis (Novozymes) B's gearing of this year was 0.10292847. Novonesis (Novozymes) B's gearing of last year was 0. ==> Last year is lower than this year ==> Score 0.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Mar25)=Total Current Assets/Total Current Liabilities
=14513.89/8728.174
=1.66287817

Current Ratio (Last Year: Dec23)=Total Current Assets/Total Current Liabilities
=9462.136/7249.956
=1.30513013

Novonesis (Novozymes) B's current ratio of this year was 1.66287817. Novonesis (Novozymes) B's current ratio of last year was 1.30513013. ==> This year's current ratio is higher. ==> Score 1.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Novonesis (Novozymes) B's number of shares in issue this year was 468.1. Novonesis (Novozymes) B's number of shares in issue last year was 277.595. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=17929.232/36631.076
=0.48945415

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=12110.501/22338.325
=0.54214007

Novonesis (Novozymes) B's gross margin of this year was 0.48945415. Novonesis (Novozymes) B's gross margin of last year was 0.54214007. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Dec23)
=36631.076/28393.116
=1.29013934

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Dec22)
=22338.325/27940.191
=0.79950509

Novonesis (Novozymes) B's asset turnover of this year was 1.29013934. Novonesis (Novozymes) B's asset turnover of last year was 0.79950509. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+1+0+1+0+1+0+0+1
=5

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Novonesis (Novozymes) B has an F-score of 5 indicating the company's financial situation is typical for a stable company.

Novonesis (Novozymes) B  (OCSE:NSIS B) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Novonesis (Novozymes) B Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of Novonesis (Novozymes) B's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Novonesis (Novozymes) B Business Description

Address
Krogshoejvej 36, Bagsvaerd, DNK, 2880
Novonesis was formed in 2024 through the merger of Novozymes and Chr. Hansen. Following the merger, the company became the world leader in industrial enzymes and microbial solutions, with a nearly 50% market share in both. The firm supplies a wide range of industry groups: household care, food and beverages, bioenergy, agriculture and feed, technical and pharmaceuticals. Its biological solutions create value for its customers by improving yield efficiency and performance, while saving energy and generating less waste. The company is headquartered in Denmark, employs around 10,000 people, and works across more than 30 research and development and application centers and 23 manufacturing sites.

Novonesis (Novozymes) B Headlines

No Headlines